Absci's AI-Designed Hair-Loss Drug Clears an Early Safety Hurdle — But Can a $1 Billion Bet Survive the Long Road to Approval?

Shares of Absci Corp surged nearly 20% in pre-market trading to $8.88 after the company reported positive interim Phase 1 data for its lead hair-loss drug candidate, an AI-designed antibody targeting the prolactin receptor. The results are the first human evidence that Absci's generative-AI drug design platform can produce a viable clinical asset — a make-or-break question for a company burning cash with virtually no revenue.

• The Drug Appeared Safe, and Its Long-Lasting Effect Could Be a Selling Point. The drug was well tolerated across all single ascending dose cohorts, with an estimated half-life of at least 65 days — long enough to support a dosing schedule of just two or three injections over six months. That convenience factor matters enormously in a market where the only two FDA-approved drugs, minoxidil and finasteride, require daily use and come with well-known limitations. In preclinical mouse studies, the antibody showed statistically superior hair regrowth compared to minoxidil. If that translates to humans, Absci would have a genuinely differentiated product.

• The Hair-Loss Market Is Massive but Crowded with Newcomers. The global androgenetic alopecia market was valued at roughly $3 billion in 2023 and is projected to reach $7.3 billion by 2034.

An estimated 50 million men and 30 million women in the U.S. alone are affected. But Absci isn't alone: Pelage Pharmaceuticals announced positive Phase 2a results for its own novel hair-loss treatment in mid-2025. Competition will intensify well before Absci's drug could reach the market.

• Proof-of-Concept Data Later This Year Is the Real Catalyst. Today's readout confirmed safety, not efficacy — the drug's ability to actually regrow hair. Absci expects interim proof-of-concept data in the second half of 2026, with full results in early 2027. That upcoming readout will determine whether the stock's rally has legs or fizzles.

• Cash Is Adequate but the Runway Isn't Infinite. The company held $125.7 million in cash as of March 31, projected to fund operations into the first half of 2028. Yet its net loss was $29.6 million last quarter alone , and Q1 revenue was a mere $0.2 million. A future capital raise — which would dilute existing shareholders — remains likely if the drug advances into larger trials. Shares outstanding already grew 31% in the past year.